CCND1 and CDKN1B polymorphisms and risk of breast cancer.

BACKGROUND AND OBJECTIVES Previous studies have shown alterations in the cell cycle regulatory proteins in breast carcinomas. However, the results of these studies remain controversial. Cyclin D1 (CCND1) and p27(KIP1) (CDKN1B) are two essential regulators of cell cycle progression. This study aimed to investigate the associations of CCND1 A870G and CDKN1B C79T polymorphisms with breast cancer risk. PATIENTS AND METHODS Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine the genotype and allelic frequencies of polymorphisms. Seventy-eight breast cancer patients and 84 age-matched healthy controls were included in the study. RESULTS Frequencies of CT genotype and T allele of CDKN1B were found to be higher in breast cancer patients than in controls (p=0.013, OR: 1.514 95% CI: 1.086-2.114.15; p=0.007, OR=1.496; 95% CI: 1.111-2.014, respectively). The frequency of AA genotype of CCND1 was decreased in hormone receptor- (estrogen and progesterone receptors) negative patients with breast cancer (p<0.049, OR=0.286; 95% CI: 0.071-1.142) CONCLUSIONS Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.

[1]  B. Ponder,et al.  Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. , 2008, Carcinogenesis.

[2]  H. Kamada,et al.  Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner , 1998, Oncogene.

[3]  M. Peters,et al.  Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. , 2004, Oncology reports.

[4]  X. Shu,et al.  Association of cyclin D1 genotype with breast cancer risk and survival. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  C. Yip,et al.  Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. , 2008, Neoplasma.

[6]  J. Diehl,et al.  An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. , 2003, Cancer research.

[7]  Robert L. Sutherland,et al.  Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[8]  J. Slingerland,et al.  Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer , 2003, Breast Cancer Research.

[9]  P. K. Davis,et al.  Vivo Cyclin-dependent Kinase Complexes in 1 Tumor Suppressor Protein by G Differential Regulation of Retinoblastoma , 2001 .

[10]  R. Sutherland,et al.  Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  N Thatcher,et al.  Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.

[12]  M. Hoopmann,et al.  The V109G Polymorphism of the p27 Gene CDKN1B Indicates a Worse Outcome in Node-Negative Breast Cancer Patients , 2004, Tumor Biology.

[13]  A. Koff,et al.  A U-Rich Element in the 5′ Untranslated Region Is Necessary for the Translation of p27 mRNA , 2000, Molecular and Cellular Biology.

[14]  R. Sutherland,et al.  Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models , 2001, Breast Cancer Research.

[15]  Chien‐An Sun,et al.  Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1 , 2007, Breast Cancer Research and Treatment.

[16]  Hongbing Shen,et al.  Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women , 2006, International journal of cancer.

[17]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[18]  K. Hemminki,et al.  Single nucleotide polymorphisms in breast cancer. , 2004, Oncology reports.

[19]  T. Illig,et al.  Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors , 2009, International journal of cancer.

[20]  Douglas F. Easton,et al.  Common Genetic Variation in Candidate Genes and Susceptibility to Subtypes of Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[21]  R. Bostick,et al.  Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. , 2003, Cancer research.

[22]  B. Paulweber,et al.  The 870G>A Polymorphism of the Cyclin D1 Gene is not Associated with Breast Cancer , 2003, Breast Cancer Research and Treatment.

[23]  B. Iacopetta,et al.  Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. , 2003, Anticancer research.

[24]  A. Senderowicz,et al.  Cyclin D1 Splice Variants , 2003, Journal of Biological Chemistry.

[25]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[26]  N. Probst-Hensch,et al.  The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. , 2005, Carcinogenesis.

[27]  M. Loda,et al.  Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN , 2000, Molecular and Cellular Biology.

[28]  H. Ozçelik,et al.  Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[29]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.